Shots:
Travere has entered into an exclusive licensing & collaboration agreement with Everest Medicines for the development & commercialization of civorebrutinib (EVER001) worldwide (excl. China & certain countries in East & Southeast Asia)
As per the deal, Everest will receive $112.5M upfront & ~$1.03B in cash payments tied to development, regulatory & commercial milestones across…
